(Reuters) - Pfizer Inc and BioNTech <22UAy.DE> could secure emergency U.S. and European authorization for their COVID-19 vaccine next month after final trial results showed it had a 95% success rate and no serious side effects, the drugmakers said on Wednesday.

from Current Affairs https://ift.tt/3nDhwti
via latest news of jobs